Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?

Link to article at PubMed

Icon for Elsevier Science Related Articles

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?

J Microbiol Immunol Infect. 2020 May 25;:

Authors: Owa AB, Owa OT

Abstract
Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitable treatment. A recent randomised control trial compared lopinavir/ritonavir with standard care among 199 patients with severe Covid-19 infection and concluded that there was no significant reduction in mortality rate with lopinavir/ritonavir. However, there are a few important lessons which may be learnt from the study apart from the statistical reduction in mortality rate. There was a numerical reduction in mortality rate, less intensive care unit stay and less complications in the lopinavir-ritonavir group. This article points out some of those important lessons with some suggestions for future clinical trials.

PMID: 32474026 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.